Boston, Sept. 16, 2025. Q2i announced a collaboration with King’s College London to evaluate its Artificial Intelligence-powered remote drug testing technology for individuals in recovery from opioid use disorder. The company and academic partner frame the work as a response to the burden that frequent in-person drug testing places on patients, including transportation, work and family commitments. The announcement positions the technology as a complement to telehealth and hybrid treatment models where testing has previously been difficult to administer with clinical confidence.
Q2i’s system is described as AI-validated and designed for at-home use. Patients complete tests from home while providers receive secure, digitally observed results intended to meet clinical reliability standards. The platform also integrates contingency management, an evidence-based approach that uses motivational incentives to encourage engagement and adherence to treatment plans. King’s lead researcher Carol Ann Getty said advances in Artificial Intelligence improve speed and reliability for digitally supervised testing, and framed the technology as a way to reduce barriers to care without compromising clinical standards. Steven Jenkins, CEO of Q2i and recipient of the Excellence Awards CEO of the Year in Digital Health, emphasized the solution’s relevance in the U.S. and internationally.
The release notes that Q2i’s contingency management division, CMI, is positioned to expand across Europe and that the company has new offices in the UK. Q2i is described as a developer of digital health solutions that combine evidence-based practices, Artificial Intelligence technology and mobile-first design to increase access and scalability for providers. By pairing secure, AI-driven testing with behavioral interventions, Q2i aims to keep patients connected to care and support longer-term recovery outcomes. SOURCE Q2I.
